A study has uncovered how variations in a non-protein coding ‘dark matter’ region of the genome could make patients susceptible to complex autoimmune and allergic diseases such as inflammatory bowel disease. The research identifies a new potential therapeutic target for the treatment of inflammatory diseases.
